Table 2 Treatment course and prognosis of all patients
Age, Sex | Tumor size (mm) | Reason for UR-LA | Pre-treatment Regimen (course) | CA19-9 before surgery (U/ml) | Protocol GyE / Fr | Post-treatment regimen | Progression free survival (months) | Progression pattern | Status, survival time (months) after diagnosis / spacer surgery |
|---|---|---|---|---|---|---|---|---|---|
67, M | 50 | CA, SMA | None | 3267 | Proton, 67.5 / 25 | Gemcitabine | 3 | Peritoneal dissemination | Dead, 12 / 10 |
48, F | 60 | CA | Gemcitabine (2) | 598 | Proton, 67.5 / 25 | Gemcitabine | 9 | Peritoneal dissemination | Dead, 16 /11 |
68, F | 30 | CA | S-1 (2) | 35 | Proton, 70.2 / 26 | S-1 | 5 | Peritoneal dissemination | Dead, 11 / 8 |
65, M | 45 | CA | None | 1066 | Proton, 67.5 / 25 | Gemcitabine | NA | - | Dead, 10 / 9 |
55, M | 34 | CA | None | 7 | Proton, 70.2 / 26 | Gemcitabine | 18 | Liver metastasis/Peritoneal Dissemination | Dead, 22 / 21 |
44, F | 25 | CA | S-1 (1) | 102 | Proton, 70.2 / 26 | Gemcitabine | 38 | Local progression | Dead, 50 / 47 |
68, F | 31 | CA | Gemcitabine (1) | 1 | Proton, 67.5 / 25 | Gemcitabine | 16 | Liver metastasis / Local progression | Dead, 31 / 30 |
68, F | 21 | CA | Gemcitabine (1) | 127 | Proton, 67.5 / 25 | Gemcitabine | 31 | Lung metastasis | Dead, 52 / 50 |
65, F | 46 | CA, SMA | Gemcitabine plus nab-paclitaxel (6) | 860 | Proton, 67.5 / 25 | Gemcitabine | NA | - | Alive, 14 / 7 |